Search
  • All Journals
Advanced Search
Search articles by Title, Author, Keywords, DOI
Submit Manuscript
0.7Impact Factor
Advanced Search
MAP  >  Gastrointestinal Tumors
2020 Volume 7
Article Contents
Next Previous
RESEARCH ARTICLE   Open Access    

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

  • a.

    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, MN, USA

  • b.

    Fairview Health Services, Minneapolis, MN, USA

More Information
  • Corresponding author: Nicholas Lim Division of Gastroenterology, Hepatology and Nutrition Department of Medicine, University of Minnesota 420 Delaware St. SE, MMC-36, Minneapolis, MN 55455 (USA) nlim@umn.edu 
  • Background: Direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV). The impact of DAAs on recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains uncertain.
    Objective: We aimed to evaluate the risk of HCC recurrence in LT recipients cleared of HCV with DAAs at the time of LT compared to a control group of LT recipients who were viremic at the time of LT.
    Methods: The study was a single-center, retrospective cohort study of patients undergoing LT for HCV-related HCC from 2002 to 2017. We compared time to post-LT HCC recurrence in patients with a sustained virological response (SVR) from DAAs prior to LT (DAA group) to patients who were viremic at LT (HCV+ group) using Kaplan-Meier analysis. We performed a secondary analysis comparing post-LT HCC recurrence in the DAA group to LT recipients with SVR from interferon-based treatment prior to LT (IFN group).
    Results: One hundred fifty-one patients underwent LT for HCC related to HCV: 34 patients in DAA group, 95 patients in HCV+ group, and 22 in IFN group. Kaplan-Meier estimates of being HCC free were 96.2, 96.2, and 78.8% at 6, 12, and 24 months in DAA group, respectively, and 100, 98.6, and 95.8% at 6, 12, and 24 months in the HCV+ group, respectively; p = 0.08. There was no difference observed for HCC recurrence between the DAA and IFN groups. In a multivariate Cox proportional hazards model, DAA use increased the risk of post-LT HCC recurrence (HR 5.2, 95% CI 0.9–29.81, p = 0.07).
    Conclusions: A strong trend was observed on both Kaplan-Meier and multivariate analyses toward increased post-LT HCC recurrence in patients who achieved SVR prior to LT with DAAs compared to patients who were viremic at LT. Caution is required when considering pre-LT treatment of HCV with DAAs in patients with HCC.

  • Cite this article

    Nicholas Lim, Dupinder Singh, Scott Jackson, John R. Lake. 2020. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy. Gastrointestinal Tumors. 7:341 doi: 10.1159/000510341
    Nicholas Lim, Dupinder Singh, Scott Jackson, John R. Lake. 2020. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy. Gastrointestinal Tumors. 7:341 doi: 10.1159/000510341
    shu

Figures(2)  /  Tables(4)

Download PDF

Article Metrics

Article views(620) PDF downloads(375)

Other Articles By Authors

Research Article   Open Access    

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

  • a.

    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, MN, USA

  • b.

    Fairview Health Services, Minneapolis, MN, USA

  • Corresponding author: Nicholas Lim Division of Gastroenterology, Hepatology and Nutrition Department of Medicine, University of Minnesota 420 Delaware St. SE, MMC-36, Minneapolis, MN 55455 (USA) nlim@umn.edu 
  • Received: 02 January 2020
  • Accepted: 17 July 2020
  • Published online: 14 September 2020
Gastrointestinal Tumors  7,  Article number: 10.1159/000510341  (2020)  |  Cite this article

Abstract: 

Background: Direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV). The impact of DAAs on recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains uncertain.
Objective: We aimed to evaluate the risk of HCC recurrence in LT recipients cleared of HCV with DAAs at the time of LT compared to a control group of LT recipients who were viremic at the time of LT.
Methods: The study was a single-center, retrospective cohort study of patients undergoing LT for HCV-related HCC from 2002 to 2017. We compared time to post-LT HCC recurrence in patients with a sustained virological response (SVR) from DAAs prior to LT (DAA group) to patients who were viremic at LT (HCV+ group) using Kaplan-Meier analysis. We performed a secondary analysis comparing post-LT HCC recurrence in the DAA group to LT recipients with SVR from interferon-based treatment prior to LT (IFN group).
Results: One hundred fifty-one patients underwent LT for HCC related to HCV: 34 patients in DAA group, 95 patients in HCV+ group, and 22 in IFN group. Kaplan-Meier estimates of being HCC free were 96.2, 96.2, and 78.8% at 6, 12, and 24 months in DAA group, respectively, and 100, 98.6, and 95.8% at 6, 12, and 24 months in the HCV+ group, respectively; p = 0.08. There was no difference observed for HCC recurrence between the DAA and IFN groups. In a multivariate Cox proportional hazards model, DAA use increased the risk of post-LT HCC recurrence (HR 5.2, 95% CI 0.9–29.81, p = 0.07).
Conclusions: A strong trend was observed on both Kaplan-Meier and multivariate analyses toward increased post-LT HCC recurrence in patients who achieved SVR prior to LT with DAAs compared to patients who were viremic at LT. Caution is required when considering pre-LT treatment of HCV with DAAs in patients with HCC.

  • About this article
    Cite this article
    Nicholas Lim, Dupinder Singh, Scott Jackson, John R. Lake. 2020. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy. Gastrointestinal Tumors. 7:341 doi: 10.1159/000510341
    Nicholas Lim, Dupinder Singh, Scott Jackson, John R. Lake. 2020. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy. Gastrointestinal Tumors. 7:341 doi: 10.1159/000510341
    shu

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return